Blog - Page 2 of 5739 - QualityStocks

ThursdaySep 17, 2026 11:31 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced that Rodman & Renshaw initiated coverage of the company with a Buy rating and a $8 price target. The research report was led by Michael G. King Jr., director of research and senior biotechnology analyst at Rodman & Renshaw. Quantum BioPharma said the coverage is unpaid and that it provided no consideration or fees for the report. To view the full press release, visit https://ibn.fm/OC9TG About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a…

ThursdaySep 17, 2026 11:20 am

QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Joins €6.3 Million French Government-Funded DETECSEPS Sepsis Project

VolitionRx Limited (NYSE American: VNRX) announced the official launch of the DETECSEPS project for the early detection of sepsis as part of the DETECSEPS Consortium, which is receiving €6.3 million, or approximately $7.3 million, in French government funding. The project is an initiative of IHU SEPSIS, coordinated and sponsored by Assistance Publique - Hôpitaux de Paris in partnership with Hospices Civils de Lyon, IDS France and Volition. Volition will provide the project’s sole biomarker, Nu.Q NETs, while IDS France will provide its automated analyzer to measure the biomarker. DETECSEPS will evaluate an early detection approach combining a routinely used clinical score with Volition’s Nu.Q NETs H3.1 blood…

ThursdaySep 17, 2026 10:55 am

QualityStocksNewsBreaks – Silynxcom Ltd. (NYSE American: SYNX) Receives Two Consecutive Orders Totaling Approximately $400,000 for CLARUS In-Ear Headset Systems

Silynxcom (NYSE American: SYNX), a manufacturer and developer of ruggedized tactical communication headset devices and other communication accessories, announced it has received two consecutive purchase orders totaling approximately $400,000 from a leading global defense company for its CLARUS In-Ear Headset system family of products. The systems are designated for a European army, with Silynxcom saying the orders represent a further step in its expanding presence across European markets. To view the full press release, visit https://ibn.fm/AA79G About Silynxcom Ltd. Silynxcom develops, manufactures and sells ruggedized tactical protective and communication headset devices, along with related communication accessories, that have been field-tested…

ThursdaySep 17, 2026 9:45 am

Nothing Onboard: How SPARC AI Is Building a Network for GPS-Denied Positioning

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising. Overwatch returns latitude, longitude, and time in roughly a third of a second with no additional hardware or software onboard the aircraft. Ukrainian drone manufacturers producing at a scale of millions of units have been invited to connect to the network as SPARC AI’s primary delivery model. Darren Wolfe, who grew a U.S. Department of State portfolio from approximately US$5–8 million to US$79 million in under three years, now leads the company’s federal and public safety sales effort. GPS is a one-way broadcast. A…

ThursdaySep 17, 2026 9:30 am

QualityStocksNewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Featured in AINewsWire Editorial on GPS-Denied Drone Navigation

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) announced its placement in an AINewsWire editorial examining the growing need for navigation technology in GPS-denied environments. The editorial highlights SPARC AI Overwatch Positioning Network, which moves positioning off the aircraft by using existing drone telemetry to return latitude, longitude and time in under a second without additional onboard hardware, positioning the technology as a software-defined, per-device subscription model for drone fleets. To view the full press release, visit https://ibn.fm/U1SpZ About SPARC AI Inc. SPARC AI is…

ThursdaySep 17, 2026 9:10 am

QualityStocksNewsBreaks – Streamex Corp. (NASDAQ: STEX) Announces Sixth GLDY Yield Distribution

Streamex (NASDAQ: STEX), a technology company focused on commodity-market tokenization, announced that the sixth yield payment for GLDY, its yield-bearing gold asset, will be distributed Sept. 17, 2026, covering Aug. 1 through Aug. 31. The company said GLDY currently earns a targeted annualized yield of 3.5% through its institutional gold leasing program. For August, 10.617518 GLDY, representing 10.617518 ounces of gold, will be distributed, resulting in a distribution of 0.003347 ounce of GLDY per token. To view the full press release, visit https://ibn.fm/1Y0Lt About Streamex Corp. Streamex Corp. (NASDAQ: STEX) is a technology and infrastructure company focused on the tokenization…

ThursdaySep 17, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

VERAXA has appointed Raju Willener as Chief Financial Officer, effective immediately. Willener brings more than 30 years of international experience spanning investment banking, corporate finance, asset management and capital markets. His appointment comes as VERAXA advances its proprietary BiTAC platform and a pipeline centered on antibody-drug conjugates and T-cell engagers. VERAXA has reported encouraging early data for its BiTAC technologies, including an in-vitro proof of concept for its BiTAC-ADC platform. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed Raju Willener as chief financial officer, adding a finance executive with more than three decades of…

ThursdaySep 17, 2026 9:00 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (OTCQB : ETST) Uplists to OTCQB Venture Market

Earth Science Tech (OTCQB : ETST), a holding company with a diversified portfolio of distinct entities, announced its successful uplisting to the OTCQB Venture Market, effective for trading Sept. 17, 2026. The OTCQB requires companies to meet financial and reporting standards, undergo annual verification and comply with management certification requirements. To view the full press release, visit https://ibn.fm/oYq2M About Earth Science Tech, Inc. (ETST) Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine…

WednesdaySep 16, 2026 3:56 pm

QualityStocksNewsBreaks – MindWave Innovations Inc. (NYSE American: APUS) Centers Digital-Asset Strategy on MindChain and NILA

MindWave Innovations (NYSE American: APUS) is concentrating its blockchain strategy around an interconnected ecosystem consisting of MindChain, the native NILA token, MindWaveDAO, and specialized Subnets. At the core is MindChain, an Ethereum-compatible Layer 2 that the company is developing as the infrastructure for the broader platform, with NILA intended to serve as its native asset and MindWaveDAO providing a decentralized governance and community layer. The company’s Subnet architecture is designed to support specialized applications, including environmental asset tokenization through ALCI, institutional real-estate infrastructure through Nexus Global Partners, and blockchain-based insurance through BlockAssure. Rather than treating these projects as separate digital-asset…

WednesdaySep 16, 2026 3:40 pm

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Developing Next-Gen Cancer Therapies with Dual-Targeting Approach

VERAXA Biotech (NASDAQ: VRXA) is developing an oncology pipeline centered on engineered antibody therapies, with a particular focus on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting “AND-gated” approach intended to activate therapeutic effects preferentially when two tumor-associated targets are present on the same cancer cell, potentially addressing the challenge of on-target, off-tumor toxicity. The company has reported early laboratory data supporting the concept in both TCE and ADC applications, while its lead BiTAC-TCE has advanced into cell-line development and planned IND/CTA-enabling work following regulatory feedback from Germany’s Paul-Ehrlich-Institute. Separately, VERAXA’s VXA-222 bispecific…

Site Search

Company Search